Galera Therapeutics, INC. (GRTX) — SEC Filings

Overview

Galera Therapeutics, INC. (GRTX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 425 filed on Apr 14, 2026: Galera Therapeutics, Inc. filed a Form 425 on April 14, 2026, related to prospectuses and communications concerning business combinations. The company, headquartered in Malvern, PA, is involved in the pharmaceutical preparations industry.

Sentiment Summary

Across 40 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 34 neutral, 1 mixed. The dominant filing sentiment for Galera Therapeutics, INC. is neutral.

Filing Type Overview

Galera Therapeutics, INC. (GRTX) has filed 2 425, 19 8-K, 6 10-Q, 2 10-K, 1 8-K/A, 2 DEF 14A, 4 SC 13G/A, 3 SC 13G, 1 SC 13D/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (40)

• Galera Therapeutics Files Form 425 — 425 · Apr 14, 2026 Risk: low
  Galera Therapeutics, Inc. filed a Form 425 on April 14, 2026, related to prospectuses and communications concerning business combinations. The company, headquar
• Galera Therapeutics Files Form 425 — 425 · Apr 14, 2026 Risk: low
  Galera Therapeutics, Inc. filed a Form 425 on April 14, 2026, related to prospectuses and business combinations. The filing includes a 425 document and a graphi
• 8-K Filing — 8-K · Apr 9, 2026
• Galera Therapeutics Files 8-K Report — 8-K · Apr 3, 2026 Risk: low
  On April 3, 2026, Galera Therapeutics, Inc. filed an 8-K report detailing other events. The filing does not contain specific financial figures or significant bu
• Galera Narrows Losses, Pivots to Breast Cancer After Asset Sale — 10-Q · Nov 13, 2025 Risk: high
  Galera Therapeutics, Inc. (GRTX) reported a net loss of $1.388 million for the three months ended September 30, 2025, a significant improvement from the $5.581
• Galera Therapeutics Enters Material Definitive Agreement — 8-K · Oct 27, 2025 Risk: medium
  On October 21, 2025, Galera Therapeutics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive
• Galera Therapeutics Enters Material Definitive Agreement — 8-K · Oct 21, 2025 Risk: medium
  On October 21, 2025, Galera Therapeutics, Inc. filed an 8-K report to disclose the entry into a material definitive agreement. The filing does not provide speci
• Galera Therapeutics Enters Material Definitive Agreement — 8-K · Sep 3, 2025 Risk: medium
  On August 27, 2025, Galera Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose the specific details of this agreement,
• Galera Narrows Losses Amid Strategic Pivot, Faces Going Concern Doubt — 10-Q · Aug 13, 2025 Risk: high
  Galera Therapeutics, Inc. (GRTX) reported a net loss of $1.075 million for the three months ended June 30, 2025, a significant improvement from the $4.064 milli
• Galera Therapeutics Files Q1 2025 10-Q — 10-Q · May 15, 2025 Risk: medium
  Galera Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported on its financial condition, including details on common stoc
• Galera Therapeutics Files 8-K — 8-K · Apr 2, 2025 Risk: medium
  On March 31, 2025, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates the company entered into a material definitive agreement and also include
• Galera Therapeutics Files 2024 10-K — 10-K · Mar 31, 2025 Risk: medium
  Galera Therapeutics, Inc. filed its 2024 10-K on March 31, 2025, reporting on its fiscal year ending December 31, 2024. The company, operating in the pharmaceut
• Galera Therapeutics Files 8-K/A Amendment — 8-K/A · Mar 24, 2025 Risk: low
  Galera Therapeutics, Inc. filed an 8-K/A on March 24, 2025, to amend its previous 8-K filing dated December 30, 2024. This amendment pertains to financial state
• Galera Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Feb 25, 2025 Risk: medium
  Galera Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on matters submitted to a vote of security holders as of February 24, 2025. The filing in
• Galera Therapeutics Files Definitive Proxy Statement — DEF 14A · Jan 24, 2025 Risk: low
  Galera Therapeutics, Inc. filed its definitive proxy statement on January 24, 2025, for its annual meeting. The filing, under the 1934 Act, concerns the solicit
• Galera Therapeutics Files 8-K on Key Corporate Events — 8-K · Dec 31, 2024 Risk: medium
  On December 30, 2024, Galera Therapeutics, Inc. filed an 8-K report detailing several significant events. These include the entry into a material definitive agr
• Galera Therapeutics Files 8-K — 8-K · Dec 20, 2024 Risk: low
  On December 20, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates that the company is a pharmaceutical preparations company incorporated
• Galera Therapeutics Files Q3 2024 10-Q — 10-Q · Dec 13, 2024 Risk: medium
  Galera Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial information and business operations for the thir
• Galera Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Oct 18, 2024 Risk: low
  Galera Therapeutics, Inc. filed an 8-K on October 18, 2024, reporting on a submission of matters to a vote of security holders. The filing indicates that the co
• Galera Therapeutics Faces Nasdaq Delisting — 8-K · Sep 4, 2024 Risk: high
  Galera Therapeutics, Inc. filed an 8-K on August 31, 2024, to report its failure to meet the continued listing standards of the Nasdaq Capital Market. The compa
• Galera Therapeutics Files Definitive Proxy Statement — DEF 14A · Sep 3, 2024 Risk: low
  Galera Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on September 3, 2024, for its annual meeting of stockholders scheduled for October 17,
• Galera Therapeutics Appoints New Chief Medical Officer — 8-K · Aug 14, 2024 Risk: low
  Galera Therapeutics, Inc. announced on August 14, 2024, that its Board of Directors has appointed Dr. Jonathan P. Saffer as Chief Medical Officer. Dr. Saffer, w
• Galera Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: medium
  Galera Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results and provided updates on its business activi
• Galera Therapeutics Files 8-K for Regulation FD Disclosure — 8-K · Aug 8, 2024 Risk: medium
  On August 8, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning it contains material non-public infor
• Galera Therapeutics Announces Leadership Changes and New Director Appointments — 8-K · Jun 7, 2024 Risk: medium
  Galera Therapeutics, Inc. announced on June 4, 2024, the departure of its Chief Medical Officer, Dr. Norman Greenberg. The company also reported the election of
• Galera Therapeutics Faces Nasdaq Delisting Warning — 8-K · Jun 3, 2024 Risk: high
  Galera Therapeutics, Inc. announced on May 31, 2024, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The co
• SC 13G/A Filing — SC 13G/A · May 16, 2024
• Galera Therapeutics Files 8-K — 8-K · May 13, 2024 Risk: low
  On May 13, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 45 Liberty Blvd, S
• Galera Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  Galera Therapeutics, Inc. (GRTX) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Galera Therapeutics, Inc. filed a 10-Q report for the period endi
• Galera Therapeutics Files 8-K: Material Agreements and Shareholder Rights — 8-K · May 3, 2024 Risk: medium
  On May 2, 2024, Galera Therapeutics, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in this 8-K filing. The filing also
• SC 13G/A Filing — SC 13G/A · May 1, 2024
• SC 13G Filing — SC 13G · Apr 16, 2024
• SC 13G/A Filing — SC 13G/A · Apr 3, 2024
• Galera Therapeutics Files 8-K on Financials — 8-K · Mar 28, 2024 Risk: low
  On March 28, 2024, Galera Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• Galera Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk: medium
  Galera Therapeutics, Inc. (GRTX) filed a Annual Report (10-K) with the SEC on March 28, 2024. Galera Therapeutics, Inc. filed its 2023 Form 10-K on March 28, 20
• Galera Therapeutics Faces Delisting Notice — 8-K · Mar 27, 2024 Risk: high
  Galera Therapeutics, Inc. filed an 8-K on March 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's principa
• Sofinnova Amends Galera Therapeutics Stake — SC 13D/A · Feb 20, 2024 Risk: medium
  Sofinnova Venture Partners IX, L.P. and its affiliates, including Sofinnova Management IX, L.L.C. and Dr. James I. Healy, filed an Amendment No. 2 to their Sche
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Yair Schneid Takes 13.073% Stake in Galera Therapeutics — SC 13G · Jan 17, 2024
  Yair Schneid, an individual investor, reported beneficial ownership of 7,110,801 shares of Galera Therapeutics, Inc. (GRTX) common stock as of January 5, 2024.
• GSA Capital Discloses 3.89M Share Stake in Galera Therapeutics — SC 13G · Jan 2, 2024
  GSA Capital Partners LLP, a UK-based investment firm, reported owning 3,892,561 shares of Galera Therapeutics, Inc. common stock as of December 31, 2023. This r

Risk Profile

Risk Assessment: Of GRTX's 32 recent filings, 5 were flagged as high-risk, 16 as medium-risk, and 11 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Galera Therapeutics, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Revenue: $0
• Net Income: -$1.388M
• EPS: N/A
• Debt-to-Equity: N/A
• Cash Position: $4.473M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: N/A

Key Executives

• Dr. Chang
• Mr. Friedman
• Jonathan P. Saffer
• Dr. Norman Greenberg
• Dr. Paul J. Hastings
• Mr. David M. E. Smith
• Dr. Mel Sorensen
• Dr. James I. Healy
• Nathalie Auber

Industry Context

Galera Therapeutics operates in the highly competitive biotechnology sector, specifically focusing on oncology therapeutics. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Recent trends include a growing emphasis on targeted therapies and personalized medicine, as well as strategic consolidations and asset sales to optimize pipelines and manage financial resources.

Top Tags

material-definitive-agreement (4) · 10-Q (4) · filing (3) · regulatory-filing (3) · corporate-action (3) · corporate-governance (3) · delisting (3) · business-combination (2) · prospectus (2) · Biotechnology (2)

Key Numbers

• SEC Accession Number: 0001193125-26-155094 — Unique identifier for the filing
• File Number: 001-39114 — Associated SEC file number
• Net Loss (9 months ended Sep 30, 2025): $4.055M — Decreased from $14.026M in 2024, indicating improved operational efficiency.
• Cash and Cash Equivalents (Sep 30, 2025): $4.473M — Down from $8.289M at Dec 31, 2024, but supplemented by a recent asset sale.
• Accumulated Deficit (Sep 30, 2025): $460.4M — Highlights significant historical losses and ongoing financial challenges.
• Proceeds from Asset Sale (Oct 2025): $3.5M — Expected to fund operating expenses for at least twelve months.
• Series B Preferred Shares Issued: 119,318 — Issued to Nova Pharmaceuticals securityholders as part of the acquisition.
• Common Shares Outstanding (Nov 12, 2025): 75,462,390 — Reflects the current share count after recent equity activities.
• R&D Expenses (9 months ended Sep 30, 2025): $0.307M — Significantly reduced from $3.223M in 2024, reflecting the strategic shift.
• G&A Expenses (9 months ended Sep 30, 2025): $4.227M — Reduced from $9.307M in 2024, indicating cost-cutting measures.
• Net Proceeds from Private Placement (Dec 2024): $2.9M — Provided capital, with $0.6M received in January 2025.
• Liquidity Runway: 12 months — Expected duration of funding from existing cash and asset sale proceeds.
• SEC File Number: 001-39114 — Identifies the company's filing history with the SEC.
• EIN: 46-1454898 — Employer Identification Number for tax purposes.
• Net Loss (Q2 2025): $1.075M — Reduced from $4.064M in Q2 2024, a 73.5% decrease

Frequently Asked Questions